Shares of Granules India rallied up 2% in early trade on August 4 after the company completed an inspection by the USFDA (United States Food and Drug Administration).

Granules Pharmaceuticals, Inc (GPI), the wholly owned subsidiary of Granules India, located in Chantilly, Virginia, USA, has completed the FDA Post-marketing Adverse Drug Experience (PADE) inspection for all its subsidiaries in the US that includes Granules India.

The inspection covered the receipts, evaluations, PADE surveillance, and reporting system for the marketed drug worldwide.

The inspection was held between July 31 to August 3 and concluded with zero observation.

This was the company’s fourth audit since March with zero observations.

The company’s board of directors are set to meet on August 9 to discuss and approve the un-audited financial results for the June quarter of the current fiscal year.

At 11:30 am, the shares of Granules India were trading at Rs 319.45 or 0.39% above its previous close of Rs 318.20 on NSE.